Managing ANCA-associated vasculitis during COVID-19 pandemic: a single-center cross-sectional studyArticle Published on 2022-12-012022-11-15 Journal: Rheumatology International [Category] 바이오마커, 진단, [키워드] Active disease ANCA-associated vasculitis Care clinical manifestations Cohort conducted COVID-19 COVID-19 infection COVID-19 severity Critical cross-sectional Cyclophosphamide death demographic died Disease activity Features Follow-up General population Immunosuppressant increased risk India Infection managing moderate non-COVID-19 patient not differ ocular outcome Patient patients patients died predicted receiving regimen required risk of COVID-19 rituximab SARS-CoV-2 severity single-center Supplemental oxygen therapy the patient Treatment Univariate analysis Vasculitis [DOI] 10.1007/s00296-022-05177-2 PMC 바로가기
Impact of the New Coronavirus Infection on the Immune System of Children and Adolescents in the Region of the Russian FederationArticle Published on 2022-10-212022-11-15 Journal: International Journal of Environmental Research an [Category] COVID19(2023년), SARS, 진단, [키워드] absence Active disease Adolescent age analysed analyses Analysis biochemical carried categories caused CD3+CD4+ cellular immunity changes in children Clinical features consequence COVID-19 deviation Diagnosis disease disease stage Epidemiology Federation FIVE flow cytometry group growth Human immune system IgA IgG IgG and IgM IgM Immune status immune system Immunity Immunoglobulin immunograms immunological immunology immunoregulation Impact Infection interval introduced laboratory diagnosis lack leukocytes Lymphocytes methodology Mutation New New coronavirus NK cell pandemic pathogen Patient patients Perm Krai phagocytic phagocytosis professional public health QR code Quantitative analysis Racial Region Research Russian population SARS-CoV-2 SARS-CoV-2 vaccination selected serological severity System T helper the disease Treatment was performed [DOI] 10.3390/ijerph192013669 PMC 바로가기
COVID-19 Vaccination in Autoimmune Diseases (COVAD) study: Vaccine safety in idiopathic inflammatory myopathiesArticle Published on 2022-10-012022-11-15 Journal: Muscle & nerve [Category] 진단, [키워드] Active disease ADE ADEs adverse event analyzed Autoimmune benefit BNT162b2 collected comparable COVID-19 COVID-19 vaccination dermatomyositis Descriptive statistics disease dose evaluate HCs healthy control higher risk Hydroxychloroquine IBM Immunoglobulin impacted inactive Inflammatory inflammatory disorder International interquartile range investigated IQR less lower risk Major median age multivariable Myopathy myositis nine Odds ratio outcome Patient Pfizer postvaccination Rash recipients reported rheumatology risk severe COVID-19 vaccination Vaccine was performed [DOI] 10.1002/mus.27681 PMC 바로가기
Reimagining the status quo: How close are we to rapid sputum-free tuberculosis diagnostics for all?현상 유지: 우리는 모두를 위한 가래 없는 신속한 결핵 진단에 얼마나 근접하고 있습니까?Review Published on 2022-04-012022-09-11 Journal: EBioMedicine [Category] MERS, 진단, 치료제, [키워드] Active disease Affect applied artificial intelligence automated capillary blood Care cascade Chest complement confirmation COVID-19 Critical diagnosed Diagnosis diagnostic diagnostics difficulty evaluate expand help Innovation lack limitation Non-sputum point-of-care Radiography Rapid reducing Reference standards researcher resource sputum TB patient Triage Tuberculosis urgency [DOI] 10.1016/j.ebiom.2022.103939 PMC 바로가기 [Article Type] Review
Effectiveness of the BNT162b2mRNA COVID-19 vaccine in patients with hematological neoplasms in a nationwide mass vaccination settingClinical Trial Published on 2022-03-102022-10-05 Journal: Blood [Category] SARS, 임상, [키워드] 1:1 95% CI Active disease Analysis controls COVID-19 COVID-19 immunity COVID-19 infection COVID-19 vaccine COVID-19-related death doses Effectiveness ENhance evaluated hematological Hospitalization humoral immune system Immunity increased risk Infection mRNA BNT162b2 vaccine neoplasm Neoplasms observation outcome Patient patient population patients patients receiving treatment polymerase chain receiving recipient risk severe COVID-19 symptomatic therapy Treatment vaccinated individual vaccination vaccine dose [DOI] 10.1182/blood.2021013768 PMC 바로가기 [Article Type] Clinical Trial
Cellular and humoral immunogenicity of the mRNA-1273 SARS-CoV-2 vaccine in patients with hematologic malignancies혈액암 환자에서 mRNA-1273 SARS-CoV-2 백신의 세포 및 체액 면역원성Article Published on 2022-02-082022-09-12 Journal: Blood advances [Category] COVID19(2023년), MERS, SARS, 진단, [키워드] Active disease acute respiratory syndrome age anti-CD20 therapy Anti-SARS-CoV-2 S assays B-cell cellular cellular response coronavirus diagnosed disease Elecsy evaluate GVHD hematologic Hematologic malignancy humoral Humoral immunity humoral immunogenicity Humoral response immunoassay Immunosuppressive agents Immunosuppressive treatment implication interferon-γ LIAISON lymphopenia management Messenger RNA mRNA mRNA-1273 mRNA-1273 vaccine observation Patient patients patients treated preserved recent SARS-CoV-2 SARS-CoV-2 vaccine second dose shown T-cell T-cell Response the SARS-CoV-2 Treatment Vaccine were measured [DOI] 10.1182/bloodadvances.2021006101 PMC 바로가기 [Article Type] Article
Impact of the Lockdown Due to the COVID-19 Pandemic on Patients With Inflammatory Bowel DiseaseMedicine Published on 2021-12-102022-10-31 Journal: Frontiers in Medicine [Category] COVID-19, [키워드] 95% CI Active disease affected age Analysis bowel conducted coronavirus disease COVID-19 COVID-19 pandemic Crohn's disease disease Disease activity disorder Effect Enrollment environmental factors exacerbated Factor Follow-up Government hospital IBD illnesses Impact Improving independent Inflammatory bowel disease intestinal Japan lockdown Logistic regression analysis management Mental multivariate Odds ratio outcome pandemic Patient patients Psychological questionnaire reported sleep quality Stress subsequent ulcerative colitis worsened [DOI] 10.3389/fmed.2021.649759 PMC 바로가기 [Article Type] Medicine
Therapies for inflammatory bowel disease do not pose additional risks for adverse outcomes of SARS-CoV-2 infection: an IG-IBD studyObservational Study Published on 2021-12-012022-10-05 Journal: Alimentary pharmacology & therapeutics [Category] SARS, 임상, [키워드] Active disease adverse outcome adverse outcomes age anti-TNF Asymptomatic build cohort study Comorbidity Course COVID-19 COVID-19 in patient death disease evaluated General population greater help higher risk hospitalisation IBD identify Immune-mediated Inflammatory bowel disease inflammatory disease lower risk medication moderate multivariable analyses multivariable logistic regression obesity outcome outcomes Patient patients Pneumonia risk risk factor Risk factors SARS-CoV-2 SARS-COV-2 infection severe COVID-19 significantly therapy ulcerative colitis ventilatory support was used [DOI] 10.1111/apt.16663 PMC 바로가기 [Article Type] Observational Study
COVID-19 in Patients With Hematologic Malignancies: A Single Center Retrospective StudyOncology Published on 2021-10-282022-10-31 Journal: Frontiers in Oncology [Category] COVID-19, [키워드] Active disease Affect Asymptomatic cardiovascular disease Care center co-morbidity COVID COVID-19 death rates described diagnosed with COVID-19 Diagnosis died disease disease severity had more Hematologic malignancy highest Hospitalization ICU leukemia lymphoid lymphoma majority malignancy median age Mild morbidity and mortality Mortality Multiple myeloma Novel coronavirus overall mortality Patient Patients with cancer patients with HM reported required smoking with COVID-19 [DOI] 10.3389/fonc.2021.740320 PMC 바로가기 [Article Type] Oncology
Extended intervals for wet AMD patients with high retreatment needs: informing the risk during COVID-19, data from real-world evidence재치료가 필요한 습성 AMD 환자를 위한 연장된 간격: COVID-19 기간 동안 위험 알리기, 실제 증거 데이터Article Published on 2021-10-012022-09-12 Journal: Eye (London, England) [Category] MERS, SARS, 임상, 진단, [키워드] Active disease adjusted Age-related macular degeneration AMD clinician COVID-19 COVID-19 pandemic criteria Evidence Extended extension eye four group increase in injection interval lesion mitigate occurred outcome pandemic Patient physician reduce reducing remained Retinal risk risk of COVID-19 stratified the mean Treatment [DOI] 10.1038/s41433-020-01315-x PMC 바로가기 [Article Type] Article